What amount has Cycurion authorized for share repurchase?

Cycurion's Board authorized a $500,000 share repurchase program, as announced by CEO Kevin Kelly on August 26, 2026. The company indicated it is managing liquidity carefully and deliberately as it executes the program.

How does this buyback relate to the company's operational performance?

The buyback authorization coincides with significant operational improvements: gross margin expanded from 6.1% in Q2 2025 to 29.1% in Q2 2026, net debt was cut by more than 50% since year-end 2024, and the company signed a 10-year, $54.6 million HHS contract. These metrics support management's confidence in the business direction.

What is the execution mechanism for this repurchase?

The execution mechanism is not specified in this filing. Management stated it is managing liquidity carefully but did not disclose whether the program will use open-market purchases, a 10b5-1 plan, an ASR, or another method.

Why is Cycurion implementing a reverse split along with the buyback?

According to CEO Kelly, the 1-for-8 reverse split is a deliberate step to clear a listing requirement and was sized only after the company obtained shareholder authority. The CEO characterized it as a step to allow the market to see the stronger business underneath, not as a reset.

What is Cycurion's stated financial target?

Management's target is to achieve break-even, profitability, and a cash-positive operating position by Q2 2027, a milestone CEO Kelly said he is personally accountable for. This provides a near-term benchmark for the company's turnaround progress.

What revenue visibility does the company have?

Cycurion disclosed $15–17 million of firmly committed revenue in each of 2026, 2027, and 2028, plus a $34 million open pipeline. The company expects the new HHS contract to contribute more than $5 million in annual recurring revenue starting in November 2026.

CYCUW 8-K Filed 2026-08-28 New authorization

Cycurion authorizes $500K share repurchase program

Board authorization comes as company reports 29.1% gross margin and signs $54.6M government contract

Authorization$500K

MechanismNot specified

What the filing says

Cycurion, Inc. (NASDAQ: CYCU) announced authorization of a $500,000 share repurchase program, as disclosed in a shareholder letter from Chairman and Chief Executive Officer L. Kevin Kelly on August 26, 2026. The authorization was accompanied by a broader operational update in which management highlighted margin expansion to 29.1% in Q2 2026 (up from 6.1% in Q2 2025), a 10-year, $54.6 million contract award with HHS, and debt reduction of more than 50% since year-end 2024.

According to Kelly's letter, the Board authorized the buyback program as part of capital management strategy, with management noting it is "managing liquidity carefully and deliberately as we execute." The execution mechanism is not specified in the filing. The $500,000 authorization represents a modest program relative to the company's recent contract wins and operational improvements.

The buyback announcement occurred in the context of a 1-for-8 reverse stock split, which the CEO characterized as a step to clear a listing requirement and allow the market to see the company's "stronger, higher-margin business." Management also disclosed multi-year revenue visibility, including $15–17 million of firmly committed revenue in each of 2026, 2027, and 2028, plus a $34 million open pipeline.

On the capital side, the Board has authorized a $500,000 share repurchase program. We are managing liquidity carefully and deliberately as we execute. — Cycurion, Inc. 8-K filing · View on SEC EDGAR →

What this means

The $500,000 buyback authorization is modest in absolute terms but signals management confidence in operational turnaround and capital discipline. Cycurion reported substantial margin improvement and new government revenue, reducing debt significantly year-over-year. The buyback occurs alongside a 1-for-8 reverse split; combined, these actions suggest management is focused on capital efficiency and maintaining listed-company status while the underlying business stabilizes. The modest size of the repurchase program relative to the company's market capitalization indicates a cautious approach to capital allocation consistent with management's stated focus on achieving profitability by Q2 2027.

Frequently asked questions

What amount has Cycurion authorized for share repurchase?: Cycurion's Board authorized a $500,000 share repurchase program, as announced by CEO Kevin Kelly on August 26, 2026. The company indicated it is managing liquidity carefully and deliberately as it executes the program.
How does this buyback relate to the company's operational performance?: The buyback authorization coincides with significant operational improvements: gross margin expanded from 6.1% in Q2 2025 to 29.1% in Q2 2026, net debt was cut by more than 50% since year-end 2024, and the company signed a 10-year, $54.6 million HHS contract. These metrics support management's confidence in the business direction.
What is the execution mechanism for this repurchase?: The execution mechanism is not specified in this filing. Management stated it is managing liquidity carefully but did not disclose whether the program will use open-market purchases, a 10b5-1 plan, an ASR, or another method.
Why is Cycurion implementing a reverse split along with the buyback?: According to CEO Kelly, the 1-for-8 reverse split is a deliberate step to clear a listing requirement and was sized only after the company obtained shareholder authority. The CEO characterized it as a step to allow the market to see the stronger business underneath, not as a reset.
What is Cycurion's stated financial target?: Management's target is to achieve break-even, profitability, and a cash-positive operating position by Q2 2027, a milestone CEO Kelly said he is personally accountable for. This provides a near-term benchmark for the company's turnaround progress.
What revenue visibility does the company have?: Cycurion disclosed $15–17 million of firmly committed revenue in each of 2026, 2027, and 2028, plus a $34 million open pipeline. The company expects the new HHS contract to contribute more than $5 million in annual recurring revenue starting in November 2026.

authorization small-cap cybersecurity rule-10b-18 liquidity-management

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.